Association of the plasma xanthine oxidoreductase activity with the metabolic parameters and vascular complications in patients with type 2 diabetes

[1]  M. Furuhashi.  New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. , 2020, American journal of physiology. Endocrinology and metabolism.

[2]  G. Kocic,et al.  A novel mechanism of vitamin D anti-inflammatory/antioxidative potential in type 2 diabetic patients on metformin therapy , 2020, Archives of medical science : AMS.

[3]  K. Shimamoto,et al.  Differential regulation of hypoxanthine and xanthine by obesity in a general population , 2020, Journal of diabetes investigation.

[4]  S. Fukumoto,et al.  Insulin Resistance Associated with Plasma Xanthine Oxidoreductase Activity Independent of Visceral Adiposity and Adiponectin Level: MedCity21 Health Examination Registry , 2019, International journal of endocrinology.

[5]  Y. Huang,et al.  MiR-218-XOR-ROS Pathway Regulates the Progression of Nonalcoholic Steatohepatitis. , 2019, Clinical laboratory.

[6]  H. Koyama,et al.  Xanthine oxidoreductase activity correlates with vascular endothelial dysfunction in patients with type 1 diabetes , 2019, Acta Diabetologica.

[7]  L. Polito,et al.  Metabolic syndrome and cancer risk: The role of xanthine oxidoreductase , 2018, Redox biology.

[8]  S. Okamoto,et al.  Activity of xanthine oxidase in plasma correlates with indices of insulin resistance and liver dysfunction in patients with type 2 diabetes mellitus and metabolic syndrome: A pilot exploratory study , 2018, Journal of diabetes investigation.

[9]  M. Ando,et al.  Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial , 2018, Nephrology.

[10]  J. Kazama,et al.  Relationship between Xanthine Oxidoreductase Redox and Oxidative Stress among Chronic Kidney Disease Patients , 2018, Oxidative medicine and cellular longevity.

[11]  K. Shimamoto,et al.  Plasma Xanthine Oxidoreductase Activity as a Novel Biomarker of Metabolic Disorders in a General Population. , 2018, Circulation journal : official journal of the Japanese Circulation Society.

[12]  I. Kubota,et al.  Increased plasma xanthine oxidoreductase activity deteriorates coronary artery spasm , 2018, Heart and Vessels.

[13]  E. Fukusaki,et al.  Hypoxanthine Secretion from Human Adipose Tissue and its Increase in Hypoxia , 2018, Obesity.

[14]  R. Robison,et al.  A review of HPRT and its emerging role in cancer , 2018, Medical Oncology.

[15]  T. Wada,et al.  Uric acid-lowering and renoprotective effects of topiroxostat, a selective xanthine oxidoreductase inhibitor, in patients with diabetic nephropathy and hyperuricemia: a randomized, double-blind, placebo-controlled, parallel-group study (UPWARD study) , 2018, Clinical and Experimental Nephrology.

[16]  H. Tomita,et al.  Establishment of the Process in Blood Sampling and Sample Handling as a Biomarker of Hypoxia-Inducible Diseases; Plasma Hypoxanthine and Xanthine Measurement , 2018 .

[17]  Jeroen J. Bax,et al.  Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). , 2018, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[18]  Xanthine oxidoreductase activity is associated with serum uric acid and glycemic control in hemodialysis patients , 2017, Scientific Reports.

[19]  B. Hunt,et al.  Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo‐Controlled Study , 2017, Journal of the American Heart Association.

[20]  J. Mehta,et al.  Oxidative Stress in Atherosclerosis , 2017, Current Atherosclerosis Reports.

[21]  N. Ishizaka,et al.  Relationship between plasma xanthine oxidoreductase activity and left ventricular ejection fraction and hypertrophy among cardiac patients , 2017, PloS one.

[22]  Deepak L. Bhatt,et al.  Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. , 2017, The Canadian journal of cardiology.

[23]  I. Kubota,et al.  Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure. , 2017, International journal of cardiology.

[24]  M. Oka,et al.  A highly sensitive assay of human plasma xanthine oxidoreductase activity using stable isotope-labeled xanthine and LC/TQMS. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[25]  D. Miric,et al.  Xanthine Oxidase Activity in Type 2 Diabetes Mellitus Patients with and without Diabetic Peripheral Neuropathy , 2016, Journal of diabetes research.

[26]  S. Anker,et al.  Uric acid and xanthine oxidase in heart failure - Emerging data and therapeutic implications. , 2016, International journal of cardiology.

[27]  R. Guieu,et al.  Plasma Xanthine Oxidase Activity Is Predictive of Cardiovascular Disease in Patients with Chronic Kidney Disease, Independently of Uric Acid Levels , 2015, Nephron.

[28]  H. Shaltout,et al.  Allopurinol alleviates hypertension and proteinuria in high fructose, high salt and high fat induced model of metabolic syndrome. , 2015, Translational research : the journal of laboratory and clinical medicine.

[29]  C. Clase,et al.  Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis , 2015, BMC Nephrology.

[30]  M. Nakayama,et al.  Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial , 2015, Clinical and Experimental Nephrology.

[31]  L. Polito,et al.  Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme. , 2014, Biochimica et biophysica acta.

[32]  C. H. Piovesan,et al.  Xanthine Oxidase Activity Is Associated with Risk Factors for Cardiovascular Disease and Inflammatory and Oxidative Status Markers in Metabolic Syndrome: Effects of a Single Exercise Session , 2014, Oxidative medicine and cellular longevity.

[33]  A. So,et al.  Xanthine Oxidase Inhibition by Febuxostat Attenuates Experimental Atherosclerosis in Mice , 2014, Scientific Reports.

[34]  I. Hisatome,et al.  Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout , 2014, Clinical and Experimental Nephrology.

[35]  Chengfu Xu,et al.  The significance of serum xanthine oxidoreductase in patients with nonalcoholic fatty liver disease. , 2014, Clinical laboratory.

[36]  B. Afşar,et al.  The role of uric acid in the pathogenesis of human cardiovascular disease , 2013, Heart.

[37]  Dhiren P. Shah,et al.  ON OXIDATIVE STRESS AND DIABETIC COMPLICATIONS , 2013 .

[38]  Y. Shinohara,et al.  Decreased extra-renal urate excretion is a common cause of hyperuricemia , 2012, Nature Communications.

[39]  C. Baylis,et al.  Hyperuricemia as a Mediator of the Proinflammatory Endocrine Imbalance in the Adipose Tissue in a Murine Model of the Metabolic Syndrome , 2011, Diabetes.

[40]  Y. Maejima,et al.  Regulation of myocardial growth and death by NADPH oxidase. , 2011, Journal of molecular and cellular cardiology.

[41]  Ferdinando Giacco,et al.  Oxidative stress and diabetic complications. , 2010, Circulation research.

[42]  Catherine B. Chan,et al.  Reactive oxygen species and endothelial function in diabetes. , 2010, European journal of pharmacology.

[43]  A. Sanyal,et al.  Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[44]  Richard J. Johnson,et al.  Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. , 2008, JAMA.

[45]  M. Cooper,et al.  Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes , 2008, Diabetes.

[46]  R. Esper,et al.  Endothelial dysfunction in normal and abnormal glucose metabolism. , 2008, Advances in cardiology.

[47]  E. Wright,et al.  Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia , 2006, International journal of clinical practice.

[48]  C. Szabó,et al.  Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol , 2006, Pharmacological Reviews.

[49]  D. Galaris,et al.  Uric acid and oxidative stress. , 2005, Current pharmaceutical design.

[50]  U. R. Kuppusamy,et al.  Glycaemic control in relation to xanthine oxidase and antioxidant indices in Malaysian Type 2 diabetes patients , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[51]  Michael Brownlee,et al.  The pathobiology of diabetic complications: a unifying mechanism. , 2005, Diabetes.

[52]  I. Alexa,et al.  [Oxidative stress in atherosclerosis]. , 2003, Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi.

[53]  D. Harrison,et al.  Electron Spin Resonance Characterization of Vascular Xanthine and NAD(P)H Oxidase Activity in Patients With Coronary Artery Disease: Relation to Endothelium-Dependent Vasodilation , 2003, Circulation.

[54]  J. Sastre,et al.  Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. , 2002, Diabetes.

[55]  Y. Moriwaki,et al.  Determination of human plasma xanthine oxidase activity by high-performance liquid chromatography. , 1996, Journal of chromatography. B, Biomedical applications.

[56]  K. Hirano,et al.  Binding of human xanthine oxidase to sulphated glycosaminoglycans on the endothelial-cell surface. , 1993, The Biochemical journal.

[57]  R. Cohen,et al.  Free radicals mediate endothelial cell dysfunction caused by elevated glucose. , 1992, The American journal of physiology.

[58]  K. Sahlin,et al.  Changes in plasma hypoxanthine and free radical markers during exercise in man. , 1991, Acta physiologica Scandinavica.

[59]  J. Baynes.  Role of Oxidative Stress in Development of Complications in Diabetes , 1991, Diabetes.

[60]  O. Saugstad.  Hypoxanthine as an indicator of tissue hypoxia. A study of plasma, cerebro-spinal and brain tissue concentrations. , 1977, Journal of the Oslo city hospitals.

[61]  J. A. Brown,et al.  Glomerular Filtration Rate , 1967 .